Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul;2(4):715-718.
doi: 10.3892/etm.2011.250. Epub 2011 Apr 7.

Interleukin-28B polymorphisms are associated with an early viral response in patients receiving hepatitis C therapy

Rie Osaki  1 , Takashi Nishimura, Takayuki Takeuchi, Hirotsugu Imaeda, Yoshiaki Okumura, Makoto Shioya, Tamio Nakahara, Shigeki Bamba, Shinobu Nakajo, Yoshihide Fujiyama, Akira Andoh
Affiliations

Interleukin-28B polymorphisms are associated with an early viral response in patients receiving hepatitis C therapy

Rie Osaki et al. Exp Ther Med. 2011 Jul.

Abstract

Prediction of the efficacy of pegylated interferon (PEG-IFN) plus ribavirin (RBV) therapy against hepatitis C (HCV) infection is valuable for determining its applications. This study investigated the relationship between the early response of HCV to PEG-IFN/RBV therapy and the inter-leukin (IL)-28B genetic polymorphism in patients with HCV infection. The genotypes of IL-28B rs8099917 T>G single nucleotide polymorphism were determined in 144 patients with HCV infection. Among them, 59 were treated with PEG-IFN/RBV. The frequency of IL-28B TT homozygosity was 75.2% in patients with HCV serotype 1 and 84.6% in patients with serotype 2. Multivariate analysis showed that IL-28B TT homozygosity (P=0.014) and the platelets number (P=0.030) was associated with the early suppression of HCV-RNA at 12 weeks after the start of PEG-IFN/RBV therapy. The IL-28B polymorphism was a significant pre-treatment predictor of the response to PEG-IFN/RBV therapy in patients with HCV infection.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Early viral response of the HCV genotype 1 to pegylated interferon (PEG-IFN) plus ribavirin (RBV). Patients of HCV genotype 1 were stratified according to their IL28B allele type, and the early responses of HCV-RNA at 4, 8 and 12 weeks after the start of PEG-IFN/RBV therapy were assessed.
Figure 2.
Figure 2.
Comparison of the effects of PEG-INFα-2a and 2b on HCV positivity. Data were analyzed by the Kaplan-Meier method. There were no significant differences between the effects of the two PEG-IFNα formulations.
See this image and copyright information in PMC

References

    1. Alavian SM, Tabatabaei SV, Keshvari M, et al. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Liver Int. 2010;30:1173–1180. - PubMed
    1. Welzel TM, Morgan TR, Bonkovsky HL, et al. Variants in interferon-alpha pathway genes and response to pegylated interferon-alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2009;49:1847–1858. - PMC - PubMed
    1. Kurosaki M, Tanaka Y, Nishida N, et al. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol. 2011;54:439–448. - PubMed
    1. Yasui K, Harano Y, Mitsuyoshi H, et al. Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus. J Gastroenterol. 2010;45:95–104. - PubMed
    1. Ochi H, Maekawa T, Abe H, et al. IL-28B predicts response to chronic hepatitis C therapy-fine-mapping and replication study in Asian populations. J Gen Virol. Jan. 2011. (E-pub ahead of print). - PubMed

LinkOut - more resources